151 related articles for article (PubMed ID: 34092821)
1. Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
Zastrozhin MS; Skryabin V; Smirnov V; Zastrozhina AK; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Mar; 51(2):31-42. PubMed ID: 34092821
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
Zastrozhin MS; Skryabin V; Smirnov V; Zastrozhina AK; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Jan; 51(1):69-80. PubMed ID: 33897064
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder.
Zastrozhin ; Smirnov ; Petukhov ; Pankratenko ; Zastrozhina ; Grishina ; Ryzhikova ; Bure ; Skryabin ; Vlasovskih ; Bryun ; Sychev
Psychopharmacol Bull; 2020 Jul; 50(3):58-75. PubMed ID: 32733112
[TBL] [Abstract][Full Text] [Related]
4. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder.
Zastrozhin MS; Skryabin VY; Smirnov VV; Petukhov AE; Pankratenko EP; Zastrozhina AK; Grishina EA; Ryzhikova KA; Bure IV; Golovinskii PA; Koporov SG; Bryun EA; Sychev DA
Gene; 2020 May; 739():144513. PubMed ID: 32112986
[TBL] [Abstract][Full Text] [Related]
5. Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder.
Zastrozhin MS; Efimova AV; Skryabin V; Smirnov VV; Petukhov AE; Pankratenko EP; Pozdniakov SA; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Nov; 51(4):87-104. PubMed ID: 34887601
[TBL] [Abstract][Full Text] [Related]
6. Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder.
Zastrozhin ; Petukhov ; Pankratenko ; Grishina ; Ryzhikova ; Skryabin ; Koporov ; Bryun ; Sychev
Psychopharmacol Bull; 2020 Jul; 50(3):47-57. PubMed ID: 32733111
[TBL] [Abstract][Full Text] [Related]
7. Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder.
Zastrozhin M; Skryabin V; Smirnov V; Zastrozhina A; Grishina E; Ryzhikova K; Bure I; Golovinskii P; Koporov S; Bryun E; Sychev D
Am J Ther; 2021 Jun; 29(1):e26-e33. PubMed ID: 34117140
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.
Zastrozhin MS; Skryabin VY; Smirnov VV; Grishina EA; Ryzhikova KA; Chumakov EM; Bryun EA; Sychev DA
Can J Physiol Pharmacol; 2019 Aug; 97(8):781-785. PubMed ID: 31100205
[TBL] [Abstract][Full Text] [Related]
9. Influence of
Zastrozhin MS; Skryabin V; Rwere F; Petukhov AE; Pankratenko EP; Pozdniakov SA; Ivanchenko VA; Noskov VV; Zaytsev IA; Vinokurova NV; Horyaev DS; Vlasovskih RV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2022 Jun; 52(3):8-19. PubMed ID: 35815173
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
Zastrozhin MS; Skryabin VY; Petukhov AE; Pankratenko EP; Grishina EA; Ryzhikova KA; Torrado MV; Shipitsyn VV; Bryun EA; Sychev DA
J Psychiatr Pract; 2021 Sep; 27(5):372-379. PubMed ID: 34529603
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder.
Zastrozhin MS; Skryabin VY; Petukhov AE; Torrado MV; Pankratenko EP; Zastrozhina AK; Grishina EA; Ryzhikova KA; Shipitsyn VV; Bryun EA; Sychev DA
Pharmacogenomics J; 2021 Aug; 21(4):435-439. PubMed ID: 33608663
[TBL] [Abstract][Full Text] [Related]
12. Effects of
Zastrozhin M; Skryabin V; Petukhov A; Pankratenko E; Pozdniakov S; Ivanchenko V; Horyaev D; Vlasovskih R; Bryun E; Sychev D
J Psychopharmacol; 2022 Oct; 36(10):1146-1150. PubMed ID: 35861192
[TBL] [Abstract][Full Text] [Related]
13. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Sychev DA; Zastrozhin MS; Miroshnichenko II; Baymeeva NV; Smirnov VV; Grishina EA; Ryzhikova KA; Mirzaev KB; Markov DD; Skryabin VY; Snalina NE; Nosikova PG; Savchenko LM; Bryun EA
Drug Metab Pers Ther; 2017 Sep; 32(3):129-136. PubMed ID: 28787271
[TBL] [Abstract][Full Text] [Related]
14. Relationship of the
Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2023 Dec; 53(4):15-22. PubMed ID: 38076663
[TBL] [Abstract][Full Text] [Related]
15. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction.
Zastrozhin MS; Grishina EA; Ryzhikova KA; Smirnov VV; Savchenko LM; Bryun EA; Sychev DA
Pharmgenomics Pers Med; 2018; 11():1-5. PubMed ID: 29343979
[TBL] [Abstract][Full Text] [Related]
16. Association of
Parkhomenko AA; Zastrozhin MS; Pozdnyakov SA; Noskov VV; Zaytsev IA; Ivanchenko VA; Denisenko NP; Akmalova KA; Skryabin V; Bryun EA; Sychev DA
Psychopharmacol Bull; 2022 Oct; 52(4):52-60. PubMed ID: 36339274
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.
Zastrozhin MS; Grishina EA; Denisenko NP; Skryabin VY; Markov DD; Savchenko LM; Bryun EA; Sychev DA
Pharmgenomics Pers Med; 2018; 11():113-119. PubMed ID: 29988737
[TBL] [Abstract][Full Text] [Related]
18. Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome.
Skryabin VY; Zastrozhin MS; Grishina EA; Ryzhikova KA; Shipitsyn VV; V Barna I; Galaktionova TE; Ivanov AV; Sorokin AS; Bryun EA; Sychev DA
J Pharm Pract; 2022 Aug; 35(4):518-523. PubMed ID: 33622083
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
20. CYP3A4 activity and haloperidol effects in alcohol addicts.
Zastrozhin MS; Smirnov VV; Sychev DA; Savchenko LM; Bryun EA; Matis OA
Int J Risk Saf Med; 2015; 27 Suppl 1():S23-4. PubMed ID: 26639694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
